Outcome of children and adolescents with Down syndrome treated on Dana‐Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00–001 and 05‐001

BACKGROUND: Children and adolescents with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) are reported to have increased relapse rates and therapy-related mortality (TRM). Treatment regimens for DS-ALL patients often include therapy modifications. Dana-Farber Cancer Institute (DFCI) ALL Consortium protocols have used same risk-stratified treatment for patients with and without DS. PROCEDURES: We compared clinical and outcome data of …